Regulated information

Information relative au code de gouvernance

Lors de la réunion du Conseil d’administration du 16 décembre 2014, les administrateurs ont adopté le code de gouvernance Middlenext. Depuis 2008, Vétoquinol se référait au code AFEP-MEDEF.

Information relative au Code de Gouvernance (french)

Lors de la réunion du Conseil d’administration du 16 décembre 2014, les
administrateurs ont adopté le code de gouvernance Middlenext. Depuis
2008, Vétoquinol se référait au code AFEP-MEDEF.

Q3 2014 sales up 11.0%

The Vétoquinol Group reported Q3 2014 sales of €82.2 million, up 11.0% compared to the same period last year (up 11.1% at constant exchange rates).

Solid growth in Q2 2014: 8.8% first half net income up 4.2%

At its July 30, 2014 meeting, the Vétoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first six months of 2014.

Vétoquinol and Bioniche Life Sciences Inc. close sale of Bioniche Animal Health business

Lure, France and Belleville, Ontario, Canada, April 16, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced the closing of the sale of Bioniche’s Animal Health business to Vétoquinol. The two companies announced the signing of a share purchase agreement in February that was subject to the approval of Bioniche shareholders. At a Special Meeting of Shareholders held yesterday, 97.4% of the Shares that were voted were in favour of the transaction.

Reference products up 2.2% in Q1 2014

Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012. Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012.

Vétoquinol is eligible for new PEA-PME funds

Lure (France), April 2, 2014 – Vétoquinol confirms that it qualifies for the PEA-PME investment product in accordance with Decree n°. 2014-283 on 4 March 2014 reflecting the application of Article 70 of 2014 finance law (n°. 2013-1278 dated 29 December 2013) which set the conditions of companies’ eligibility for the PEA-PME

2013 growth driven by reference products

Lure (France), March 12, 2014 – At its March 11, 2014 meeting, the Vétoquinol SA board of directors reviewed the Group results and approved the 2013 financial statements.

Vétoquinol to acquire the animal health business of Bioniche Life Sciences Inc.

LURE, FRANCE and BELLEVILLE, ONTARIO, CANADA, February 27, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced their signing of a share purchase agreement under which Vétoquinol has agreed to purchase Bioniche’s Animal Health business for the cash purchase price of CAD$61 million.

7.8% organic growth in Q4 2013

The Vétoquinol Group posted Q4 2013 sales of €80.1 million, up +7.8% like for like from Q4 2012.

Jean-Yves RAVINET appointed Group Chief Operating Officer

Lure (France), January 7, 2014 – The Vétoquinol Group announces the appointment of Jean-Yves Ravinet as Group Chief Operating Officer.

Vétoquinol announces opening of its first decentralized R&D center in Canada

Vétoquinol to market and distribute Vetprofen in the United States

3rd quarter revenues confirm promise of
strong growth prospects for 2007

For the nine months ended September 30, 2007, Vétoquinol’s total revenues reached €166.0 M, an increase of 11.3% compared with the
corresponding period in 2006.

Reports very good first half, confirming that 2007 performance is set to surpass targets

Presentation of Vétoquinol’s results for the first half of 2007

2007 Half year results

Rapport semestriel 2007 « narratif » (french)

Suite à la publication du 26 juillet dernier, Vétoquinol a réalisé au 1er semestre 2007 un
chiffre d’affaires de 111,1 M€ contre 98,4 M€ au cours de la même période de l’exercice
précédent, soit une progression de 12,9 %.
A cours de change et périmètre constants, la progression est de 10,1 %.

Business is strong in first-half of 2007 : + 12.9%

2007 Half year Financial Report

Vétoquinol creates a subsidiary in Portugal

2006 Financial Report

Le chiffre d’affaires s’est accru de 7,6% par rapport à l’exercice précédent.
Le résultat opérationnel courant, qui s’élève à 25,6 M€, est en augmentation de 10,8%.
Enfin, le résultat net de 15,8 M€ progresse de 27,2% et représente 7,5% du chiffre d’affaires.
Cette croissance a été maîtrisée et équilibrée.

Activity Report 2006

Annual earnings for 2006: a year of good performance

Présentation des résultats 2006 de Vétoquinol (french)

Vétoquinol reports one of its industry’ strongest growth performances in 2006

Sustained revenue growth in 2006

Vétoquinol strengthens its position in the United States